Pfizer Injunction Plea vs Unilab Denied

Article excerpt

The Makati Regional Trial Court has denied Pfizer’s petition for a preliminary injunction against United Laboratories Inc. (Unilab) on patent infringement issue over Atorvastatin Calcium drug. Pfizer said it is going to file a motion for reconsideration.In a statement, Pfizer Inc., claimed that its patent over Atorvastatin Calcium, an anti-cholesterol drug, remains valid and enforceable.“Pfizer has not lost its infringement case against Unilab,” said Pfizer’s counsel Ramon S. Esguerra in a statement.Pfizer will file a motion for reconsideration as it still believes in the strong merits of its case, and to give the court a chance to re-evaluate the evidence presented before it. Pfizer is determined, as usual, to pursue with full vigor all possible legal remedies to run after infringers of its patents.According to Esguerra, they are disturbed with the order of the Makati Regional Trial Court in denying Pfizer’s application for a preliminary injunction stressing “Pfizer has presented numerous expert witnesses and evidence to prove its ownership, validity, and strength of its Atorvastatin Calcium patent, versus one witness of Unilab,” Esguerra said.Esguerra noted the unusual haste and speed with which this order has been served only to Unilab’s counsel. …